Thursday, October 01, 2015

          Drug Wars: A New Generation of Generic Pharmaceutical Delay

          New paper by Professor Robin Feldman and Research Fellow Evan Frondorf follows evolution of strategies used by pharmaceutical companies to delay entrance of generic drugs, revealing clever “games” being played out in courts, conference rooms, and laboratories across the world.
          Sample alt tag.
          “Even a few months of generic delay for one drug can prevent consumers from realizing hundreds of millions of dollars in savings,” says Feldman.

          Recent news detailing enormous spikes in prices for some drugs has brought the issue of prescription drug access back into focus with leading presidential candidates calling for reform in the midst of public outrage.

          High prices are not just plaguing a few medications with limited applications — nationwide spending on drugs increased 12 percent in just the last year. One reason for climbing prices might be a lack of generic competition for some drugs.

          When the US introduced a regulatory pathway in the 1980s to speed generic drugs to market, it ushered in a new era for medicine. Now, more than 80% of drugs have a generic equivalent, and consumers save hundreds of billions of dollars each year through generic prescriptions. However, as drugs face patent expiration or the threat of generic competition, pharmaceutical companies have long taken drastic measures to keep generic versions of their drugs off the market.

          A new paper by UC Hastings Professor Robin Feldman and Research Fellow Evan Frondorf follows the evolution of strategies used by pharmaceutical companies to delay the entrance of generic drugs, revealing clever “games” being played out in courts, conference rooms, and laboratories across the world.

          The paper — titled “Drug Wars: A New Generation of Generic Pharmaceutical Delay” — is forthcoming in the Harvard Journal on Legislation. A draft is available at http://ssrn.com/abstract=2659308

          “Even a few months of generic delay for one drug can prevent consumers from realizing hundreds of millions of dollars in savings,” says Feldman. “In turn, that additional period of exclusivity — an extended monopoly period — is extremely valuable to a pharmaceutical company.”

          Early strategies focused on making deals with prospective generic manufacturers to stay out of the market, commonly known as “reverse payments” and “pay-for-delay settlements.” But as these settlements have come under intense government and public scrutiny, Feldman and Frondorf show how companies have moved away from these “Generation 1.0” settlements, employing ever-more complex strategies.

          “Generation 2.0” strategies employ the pay-for-delay model while obscuring the monetary payment behind side deals and other considerations, and include what the authors call “boy scout clauses” — agreements to behave honorably that actually mask anticompetitive collusion. And the newest generation moves from collusion to obstruction. “Generation 3.0” makes use of complicated administrative processes, regulatory schemes, and minimal drug modifications to prevent generics from getting to market. They include the following:

          • “Product hopping” — a last-minute switch to a “new and improved” form of a drug just before generic competition is scheduled to begin on the original drug
          • “REMS delay” — using FDA safety protocols as an excuse not to cooperate with generic drug makers
          • “Citizen petition” — filing petitions with the FDA claiming that a generic drug should not be approved, merely to delay its entry while the FDA reviews the petition

          The paper ends with a call for reform, exploring ideas for how a new generic entry pathway might be structured.

          “To incentivize continued drug development, pharmaceutical companies must have a chance to recoup their research costs,” says Frondorf. “But the patent system is built on inventions eventually reaching the public domain, and actions meant to block generic entry are contrary to the interests of Congress, the patent system, and, importantly, consumers who would otherwise benefit from lower-cost generics.”

          ###

          Go to News Archive

          Share this Story

          Share via Facebook
          Share via TwitterShare via EmailPrint Friendly Version

          Other Recent Stories/ RSS

          Friday, February 16, 2018

          Patrick Barry '94 Takes COO Role at Legal Tech Startup Logikcull

          The cloud-based eDiscovery software company brings Barry back to business as a tech executive after a two-year sabbatical.
          Thursday, February 01, 2018

          Thinkers & Doers: January 2018

          Inaugural Exhibition of the McEvoy Foundation for the Arts – Professor Viswanathan co-authors SSRN’s "Top Paper of 2017" – When Deportation is a Death Sentence – A project to “restate” copyright law – Alum named 2018 Antitrust Lawyer of the Year – Posh Hotels & Swanky Cocktails in the Tenderloin – Calling out racists actually good for health – Bay Area Corporate Counsel Winners – and much more
          Monday, January 29, 2018

          Justice Lidia Stiglich '95 Brings Compassion to the Bench

          She is taking a “people-centric” approach as the first openly gay justice to serve on the Nevada Supreme Court.
          Thursday, January 18, 2018

          1L Cindy Muro Receives Scholarship for Domestic Violence Advocacy

          A survivor of abuse herself, Muro now strives to do everything in her power to help people help themselves and create a platform for individuals to be heard.
          Thursday, January 11, 2018

          Message from Dean Faigman: On the passing of Professor Geoff Hazard

          “A deeply inspiring teacher, a mentor to many generations of students and faculty, an enormously influential scholar, and a dear friend to so many of us.”
          Go to News Archive